21st Century Cures: Device Provisions
Executive Summary
Dozens of reforms impacting the medtech sector were passed by the US House Nov. 30 in a compromise version of the 21st Century Cures Act that is expected to pass the Senate and be signed by President Obama before he leaves office. Here's a breakdown of the provisions most important to device- and diagnostic-makers.
You may also be interested in...
Trump Praises Record Device Approvals, Pushes Congress To Pass 'Right-To-Try' Bills
In his Jan. 30 State of the Union address, President Trump praised US FDA for its high approval rate of devices and drugs in 2017, and urged Congress to do more by approving 'right-to-try' legislation that he says would allow terminally ill patients to gain access to experimental devices and drugs.
Combo Products Won't Get Special Review Pathway At US FDA Anytime Soon
FDA's Jeffrey Shuren and Janet Woodcock tell a Senate committee that the agency is more concerned with implementing combination product provisions from the 21st Century Cures Act than working on a novel review pathway for device/drug combination products.
Combo-Product Sponsors Gain Some Favored Changes In Final Post-Market Reporting Rule
US FDA’s final rule includes several clarifications about its scope and definitions, and includes some additional reporting requirements.